SCHEMBL5724967

SCHEMBL5724967

COC(=O)c1ccc(C#CCNC(=O)OC(C)(C)C)o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PTPN11 Q06124 1/20 0.48
ACACB O00763 1/20 0.45
HTT P42858 2/20 0.42
TSHR P16473 1/20 0.41
DDB1 Q16531 2/20 0.39
CRBN Q96SW2 2/20 0.39
ADRA2A P08913 1/20 0.38
DRD5 P21918 1/20 0.38
DRD3 P35462 1/20 0.38
P2RY6 Q15077 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25241050 0.88 PTPN11 (0.52) ALDH1A1KDM4ELMNAL3MBTL1PTPN11
SCHEMBL30463940 0.82 PTPN11 (0.50) ALDH1A1KDM4EPTPN11HTTDDB1
SCHEMBL25727094 0.82 PTPN11 (0.50) ALDH1A1KDM4EPTPN11HTTDDB1
SCHEMBL25728090 0.80 PTPN11 (0.42) PTPN11TSHRTDP1
SCHEMBL24670461 0.80 PTPN11 (0.53) KDM4EL3MBTL1PTPN11NPSR1MAPT
SCHEMBL19736947 0.78 ALDH1A1 (0.61) ALDH1A1KDM4ELMNAL3MBTL1ACACB
SCHEMBL15864554 0.76 HTT (0.58) ALDH1A1KDM4ELMNAHTTTSHR
SCHEMBL4816347 0.75 PTPN11 (0.64) PTPN11DDB1CRBNADRA2ADRD5
SCHEMBL24516781 0.74 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAL3MBTL1ACACB
SCHEMBL30463924 0.73 DDB1 (0.43) ALDH1A1PTPN11DDB1CRBNADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425517-A1 NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION PRAZER THERAPEUTICS INC. (KR) 2024-12-26 US disclosed
EP-4450490-A1 NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION Prazer Therapeutics Inc. (KR) 2024-10-23 EP disclosed
WO-2023113457-A1 NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION (주)프레이저테라퓨틱스 2023-06-22 WO disclosed
WO-2023113457-A1 NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION (주)프레이저테라퓨틱스 2023-06-22 WO disclosed
EP-0946501-B1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER (US) 2006-05-31 EP disclosed
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 US disclosed
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC 2004-09-09 US disclosed
US-6649657-B2 Administering amide to treat osteoporosis PFIZER INC. 2003-11-18 US disclosed
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLEY Q (US) 2003-06-05 US disclosed
US-6492412-B2 ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. PFIZER, INC. 2002-12-10 US disclosed
US-20020165255-A1 Osteoporosis compounds CAMERON KIMBERLY O (US) 2002-11-07 US disclosed
US-6376502-B1 PROSTAGLANDIN AGONISTS ARE USEFUL FOR THE TREATMENT OF BONE DISORDERS INCLUDING OSTEOPOROSIS. PFIZER INC. 2002-04-23 US disclosed
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLY O (US) 2002-02-07 US disclosed
US-6344485-B1 Method for treating glaucoma PFIZER INC. 2002-02-05 US disclosed
US-6288120-B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. 2001-09-11 US disclosed
US-6124314-A A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS PFIZER INC. (US) 2000-09-26 US disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 EP disclosed
EP-0911321-A2 Compounds for the treatment of osteoporosis PFIZER INC. (US) 1999-04-28 EP disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 ALDH1A1 2216/4885KDM4E 3595/4885LMNA 705/4885
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 ALDH1A1 2216/4885KDM4E 3595/4885LMNA 705/4885
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 ALDH1A1 2216/4885KDM4E 3595/4885LMNA 705/4885
US-20240425517-A1 NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION ADRM1, SUMO1, SUMO2 ALDH1A1 3989/4885KDM4E 2717/4885LMNA 2751/4885
US-20020165255-A1 Osteoporosis compounds PTGER1, PTGIR, PTGER4 ALDH1A1 2288/4885KDM4E 3461/4885LMNA 1241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.